Search research articles
Contact Us
Filters
Showing results (131-140 of 165) with videos related to
Page
of 17
Sort By:
Research Square
|
February 8, 2022
Early immune responses have long-term associations with clinical, virologic, and immunologic outcomes in patients with COVID-19
Zicheng Hu, Kattria van der Ploeg, Saborni Chakraborty, et al.
Bioorganic & Medicinal Chemistry Letters
|
November 19, 2003
New antibacterial tetrahydro-4(2H)-thiopyran and thiomorpholine S-oxide and S,S-dioxide phenyloxazolidinones
Upinder Singh, B Raju, Stuart Lam, et al.
The Lancet. Infectious Diseases
|
July 17, 2025
Efficacy and safety of obeldesivir in low-risk, non-hospitalised patients with COVID-19 (OAKTREE): a phase 3, randomised, double-blind, placebo-controlled study
Onyema Ogbuagu, Jason D Goldman, Robert L Gottlieb, et al.
Science Translational Medicine
|
January 13, 2022
Antibodies elicited by SARS-CoV-2 infection or mRNA vaccines have reduced neutralizing activity against Beta and Omicron pseudoviruses
Benjamin L Sievers, Saborni Chakraborty, Yong Xue, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America
|
April 21, 2022
Favipiravir for Treatment of Outpatients With Asymptomatic or Uncomplicated Coronavirus Disease 2019: A Double-Blind, Randomized, Placebo-Controlled, Phase 2 Trial
Marisa Holubar, Aruna Subramanian, Natasha Purington, et al.
Nature Communications
|
March 31, 2021
Peginterferon Lambda-1a for treatment of outpatients with uncomplicated COVID-19: a randomized placebo-controlled trial
Prasanna Jagannathan, Jason R Andrews, Hector Bonilla, et al.
Cell Reports. Medicine
|
May 19, 2022
TNF-α<sup>+</sup> CD4<sup>+</sup> T cells dominate the SARS-CoV-2 specific T cell response in COVID-19 outpatients and are associated with durable antibodies
Kattria van der Ploeg, Adam S Kirosingh, Diego A M Mori, et al.
Microbiology Spectrum
|
May 18, 2026
Effect of inhaled interferon-β1a on SARS-CoV-2 diversity and evolution
Gregory E Edelstein, Tatum N Sass, Rinki Deo, et al.
Medrxiv : the Preprint Server for Health Sciences
|
October 27, 2022
Fluvoxamine for Outpatient Treatment of COVID-19: A Decentralized, Placebo-controlled, Randomized, Platform Clinical Trial
Matthew W McCarthy, Susanna Naggie, David R Boulware, et al.
JAMA
|
January 12, 2023
Effect of Fluvoxamine vs Placebo on Time to Sustained Recovery in Outpatients With Mild to Moderate COVID-19: A Randomized Clinical Trial
Matthew W McCarthy, Susanna Naggie, David R Boulware, et al.
Page
of 17
Search research articles
Search
Showing results (131-140 of 165) with videos related to
Sort By:
Page
of 17
Research Square
|
February 8, 2022
Early immune responses have long-term associations with clinical, virologic, and immunologic outcomes in patients with COVID-19
Zicheng Hu, Kattria van der Ploeg, Saborni Chakraborty, et al.
Bioorganic & Medicinal Chemistry Letters
|
November 19, 2003
New antibacterial tetrahydro-4(2H)-thiopyran and thiomorpholine S-oxide and S,S-dioxide phenyloxazolidinones
Upinder Singh, B Raju, Stuart Lam, et al.
The Lancet. Infectious Diseases
|
July 17, 2025
Efficacy and safety of obeldesivir in low-risk, non-hospitalised patients with COVID-19 (OAKTREE): a phase 3, randomised, double-blind, placebo-controlled study
Onyema Ogbuagu, Jason D Goldman, Robert L Gottlieb, et al.
Science Translational Medicine
|
January 13, 2022
Antibodies elicited by SARS-CoV-2 infection or mRNA vaccines have reduced neutralizing activity against Beta and Omicron pseudoviruses
Benjamin L Sievers, Saborni Chakraborty, Yong Xue, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America
|
April 21, 2022
Favipiravir for Treatment of Outpatients With Asymptomatic or Uncomplicated Coronavirus Disease 2019: A Double-Blind, Randomized, Placebo-Controlled, Phase 2 Trial
Marisa Holubar, Aruna Subramanian, Natasha Purington, et al.
Nature Communications
|
March 31, 2021
Peginterferon Lambda-1a for treatment of outpatients with uncomplicated COVID-19: a randomized placebo-controlled trial
Prasanna Jagannathan, Jason R Andrews, Hector Bonilla, et al.
Cell Reports. Medicine
|
May 19, 2022
TNF-α<sup>+</sup> CD4<sup>+</sup> T cells dominate the SARS-CoV-2 specific T cell response in COVID-19 outpatients and are associated with durable antibodies
Kattria van der Ploeg, Adam S Kirosingh, Diego A M Mori, et al.
Microbiology Spectrum
|
May 18, 2026
Effect of inhaled interferon-β1a on SARS-CoV-2 diversity and evolution
Gregory E Edelstein, Tatum N Sass, Rinki Deo, et al.
Medrxiv : the Preprint Server for Health Sciences
|
October 27, 2022
Fluvoxamine for Outpatient Treatment of COVID-19: A Decentralized, Placebo-controlled, Randomized, Platform Clinical Trial
Matthew W McCarthy, Susanna Naggie, David R Boulware, et al.
JAMA
|
January 12, 2023
Effect of Fluvoxamine vs Placebo on Time to Sustained Recovery in Outpatients With Mild to Moderate COVID-19: A Randomized Clinical Trial
Matthew W McCarthy, Susanna Naggie, David R Boulware, et al.
Page
of 17